Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Sep 16:2022:3472722.
doi: 10.1155/2022/3472722. eCollection 2022.

Clinical Effect of Fuzheng Guben Decoction in the Treatment of Localized Prostate Cancer and Its Influence on Immune Function under Continuous Nursing Intervention

Yanling Zhou  1 , Lan Liu  2 , Lifei Gao  3
Affiliations
Randomized Controlled Trial

Clinical Effect of Fuzheng Guben Decoction in the Treatment of Localized Prostate Cancer and Its Influence on Immune Function under Continuous Nursing Intervention

Yanling Zhou et al. Contrast Media Mol Imaging. .

Retraction in

Abstract

In order to explore the clinical effect and immune function of patients with localized prostate cancer combined with continuous nursing intervention and Fuzheng Guben decoction, a total of 72 patients with prostate cancer admitted to our hospital from January 2020 to June 2021 are selected and analyzed. The patients are randomly divided into a study group and control group randomly, and the control group and the research group are treated with routine intervention and chemotherapy, continuous nursing intervention, and Fuzheng Guben decoction on the basis of chemotherapy, respectively. The incidence of postoperative urinary incontinence and other complications between the two groups are counted, and the differences of FHIT, CatD, CatL, CD68, and CD83 levels in the patients are compared. Furthermore, the total treatment response rate and self-attitude score of the two groups are compared after treatment. The experimental results demonstrate that the total effective rate and self-attitude score of patients in the study group are significantly better than those in the control group.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Urinary incontinence condition.
Figure 2
Figure 2
Expression of total tumor suppressor genes and invasion genes.
Figure 3
Figure 3
CD68 and CD83 expression in peripheral blood before treatment.
Figure 4
Figure 4
CD68 and CD83 expression in peripheral blood after treatment.
Figure 5
Figure 5
Comparison of the self-efficacy scores at hospital admission.
Figure 6
Figure 6
Comparison of self-efficacy scores at 3 months from discharge.
See this image and copyright information in PMC

References

    1. Taneja S. Re: surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. The Journal of Urology . 2018;200(2):245–246. doi: 10.1016/j.juro.2018.05.047. - DOI - PubMed
    1. Alwhaibi A., Alsanea S., Almadi B., Al-sabhan J., Alosaimi F. D. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management. The Aging Male . 2022;25(1):101–124. doi: 10.1080/13685538.2022.2053954. - DOI - PubMed
    1. Hoeh B., Wenzel M., Müller M., et al. Urethral sphincter length but not prostatic apex shape in preoperative MRI is associated with mid-term continence rates after radical prostatectomy. Diagnostics . 2022;12(3):701–702. doi: 10.3390/diagnostics12030701. - DOI - PMC - PubMed
    1. Wild K., Sharma N., Mattek N., Karlawish J., Riley T., Kaye J. Application of in-home monitoring data to transition decisions in continuing care retirement communities: usability study. Journal of Medical Internet Research . 2021;23(1):e18806–3221. doi: 10.2196/18806. - DOI - PMC - PubMed
    1. Mota J. M., Barnett E., Nauseef J., et al. Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes. Journal of Clinical Oncology . 2019;37(15_suppl):5038–5034. doi: 10.1200/jco.2019.37.15_suppl.5038. - DOI

Publication types

Substances